Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017, 36449-36454 [2017-16440]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 149 / Friday, August 4, 2017 / Notices
controlled drug such as Ibuprofen so as
not to arouse a pharmacist’s suspicion
as to the legality of a controlled
substance prescription and induce him
to fill the prescription constitutes
actionable misconduct under Factor
Five. See 77 FR at 64141. Such conduct
is, in essence, a form of subterfuge, and
may threaten public health and safety
by inducing a pharmacist into believing
a controlled substance prescription is
lawful rather than questioning its
validity and refusing to fill it. Cf. 21
U.S.C. 843(a)(3) (‘‘It shall be unlawful
for any person knowingly or
intentionally . . . to acquire or obtain
possession of a controlled substance by
misrepresentation, fraud, forgery,
deception, or subterfuge.’’).
Here, the evidence shows that at the
UC’s first visit, Respondent told him
that she ‘‘was gonna [sic] give you some
ibuprofen. Because if you[’re] filling in
Florida which I encourage you to do so
you’re on the computer list. Then . . .
for two reasons: Number one, the
pharmacists usually want a nonprescription drug, a non-controlled
substance drug rather . . . and
ibuprofen is also good for
inflammation.’’ GE 7, at 6.
At his second visit, the UC told
Respondent that a pharmacist refused to
fill the Klonopin prescription she had
issued previously. GE 9, at 9.
Respondent advised the UC to take the
prescription to another pharmacy and
told him that it is not doctor-shopping
if the pharmacist refused to fill the
prescription; she also told the UC that
she would ‘‘write that [Klonopin] and
I’ll write another non-narcotic.’’ Id. at
10. Respondent subsequently stated she
would ‘‘give [the UC] two small
prescriptions’’ for ibuprofen and ‘‘one
narcotic for each pharmacy that [he]
might have to go to.’’ Id. at 16. She
added ‘‘I want you to keep the extra
ibuprofen so if they won’t fill the
Klonopin again you have another nonnarcotic to use.’’ Id. at 17.
In advising the UC how to avoid
encountering difficulties in filling his
prescriptions for controlled substances
and in issuing non-narcotic
prescriptions to minimize any
suspicions by pharmacists, Respondent
engaged in ‘‘[s]uch other conduct which
may threaten the public health and
safety’’). See Perper, 77 FR at 64141. Cf.
Nelson A. Smith, 58 FR 65403, 65404
(1993) (holding that using strategies ‘‘to
avoid detection . . . such as falsifying
patients charts and suggesting that the
recipients of . . . illegal prescriptions
go to different pharmacies’’ is actionable
misconduct under Factor Five).
I therefore hold that the Government’s
evidence with respect to Factors Two,
VerDate Sep<11>2014
15:13 Aug 03, 2017
Jkt 241001
Four, and Five establishes that
Registrant ‘‘has committed such acts as
would render her registration . . .
inconsistent with the public interest.’’
21 U.S.C. 824(a)(4). Because Respondent
waived her right to a hearing (or to
submit a written statement in lieu of a
hearing), there is no evidence in the
record to refute the conclusion that her
continued registration is ‘‘inconsistent
with the public interest.’’ Id.
Accordingly, I will order that
Respondent’s registration be revoked
and that any pending applications be
denied.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 824(a), as well
as 28 CFR 0.100(b), I order that DEA
Certificate of Registration No.
AS1456361, issued to Marcia L. Sills,
M.D., be, and it hereby is, revoked. I
further order that any pending
application of Marcia L. Sills to renew
or modify the above registration, or any
pending application of Marcia L. Sills
for any other registration, be, and it
hereby is, denied. This Order is effective
September 5, 2017.
Dated: July 27, 2017.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2017–16442 Filed 8–3–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–470P]
Proposed Adjustments to the
Aggregate Production Quotas for
Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2017
Drug Enforcement
Administration, Department of Justice.
ACTION: Notice with request for
comments.
AGENCY:
The Drug Enforcement
Administration (DEA) proposes to
adjust the 2017 aggregate production
quotas for several controlled substances
in schedules I and II of the Controlled
Substances Act and assessment of
annual needs for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine.
SUMMARY:
Interested persons may file
written comments on this notice in
accordance with 21 CFR 1303.13(c) and
1315.13(d). Electronic comments must
DATES:
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
36449
be submitted, and written comments
must be postmarked, on or before
September 5, 2017. Commenters should
be aware that the electronic Federal
Docket Management System will not
accept comments after 11:59 p.m.
Eastern Time on the last day of the
comment period.
Based on comments received in
response to this notice, the
Administrator may hold a public
hearing on one or more issues raised. In
the event the Administrator decides in
his sole discretion to hold such a
hearing, the Administrator will publish
a notice of any such hearing in the
Federal Register. After consideration of
any comments or objections, or after a
hearing, if one is held, the
Administrator will publish in the
Federal Register a final order
establishing the 2017 adjusted aggregate
production quotas for schedule I and II
controlled substances, and an
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–470P’’ on all correspondence,
including any attachments. The Drug
Enforcement Administration encourages
that all comments be submitted
electronically through the Federal
eRulemaking Portal which provides the
ability to type short comments directly
into the comment field on the Web page
or attach a file for lengthier comments.
Please go to https://www.regulations.gov
and follow the online instructions at
that site for submitting comments. Upon
completion of your submission you will
receive a Comment Tracking Number for
your comment. Please be aware that
submitted comments are not
instantaneously available for public
view on Regulations.gov. If you have
received a Comment Tracking Number,
your comment has been successfully
submitted and there is no need to
resubmit the same comment. Paper
comments that duplicate electronic
submissions are not necessary and are
discouraged. Should you wish to mail a
paper comment in lieu of an electronic
comment, it should be sent via regular
or express mail to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
FOR FURTHER INFORMATION CONTACT:
Michael J. Lewis, Diversion Control
Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152, Telephone: (202) 598–6812.
E:\FR\FM\04AUN1.SGM
04AUN1
36450
Federal Register / Vol. 82, No. 149 / Friday, August 4, 2017 / Notices
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments
received in response to this docket are
considered part of the public record.
They will, unless reasonable cause is
given, be made available by the Drug
Enforcement Administration (DEA) for
public inspection online at https://
www.regulations.gov. Such information
includes personal identifying
information (such as your name,
address, etc.) voluntarily submitted by
the commenter.
The Freedom of Information Act
(FOIA) applies to all comments
received. If you want to submit personal
identifying information (such as your
name, address, etc.) as part of your
comment, but do not want it to be made
publicly available, you must include the
phrase ‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want made publicly
available in the first paragraph of your
comment and identify what information
you want redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be made
publicly available, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
of your comment. You must also
prominently identify confidential
business information to be redacted
within the comment.
Comments containing personal
identifying information or confidential
business information identified and
located as directed above will generally
be made available in redacted form. If a
comment contains so much confidential
business information or personal
identifying information that it cannot be
effectively redacted, all or part of that
comment may not be made publicly
available. Comments posted to https://
www.regulations.gov may include any
personal identifying information (such
as name, address, and phone number)
included in the text of your electronic
submission that is not identified as
directed above as confidential.
An electronic copy of this document
is available at https://
www.regulations.gov for easy reference.
Legal Authority and Background
Section 306 of the Controlled
Substances Act (CSA) (21 U.S.C. 826)
VerDate Sep<11>2014
15:13 Aug 03, 2017
Jkt 241001
requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
and for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. The Attorney
General has delegated this function to
the Administrator of the DEA pursuant
to 28 CFR 0.100.
The DEA established the 2017
aggregate production quotas for
substances in schedules I and II and the
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine on October 5,
2016 (81 FR 69079). That notice
stipulated that, in accordance with 21
CFR 1303.13 and 1315.13, all aggregate
production quotas and assessments of
annual need are subject to adjustment.
Analysis for Proposed Adjusted 2017
Aggregate Production Quotas and
Assessment of Annual Needs
The DEA proposes to adjust the
established 2017 aggregate production
quotas and assessment of annual needs
for certain schedule I and II controlled
substances, and the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, to be
manufactured in the United States in
2017 to provide for the estimated
medical, scientific, research, and
industrial needs of the United States, for
lawful export requirements, and for the
establishment and maintenance of
reserve stocks. These quotas do not
include imports of controlled
substances for use in industrial
processes.
In determining the proposed
adjustment, the Acting Administrator
has taken into account the criteria in
accordance with 21 CFR 1303.13
(adjustment of aggregate production
quotas for controlled substances) and 21
CFR 1315.13 (adjustment of the
assessment of annual needs for
ephedrine, pseudoephedrine, and
phenylpropanolamine). The DEA
determined whether to propose an
adjustment of the aggregate production
quotas and assessment of annual needs
for 2017 by considering: (1) Changes in
the demand for that class or chemical,
changes in the national rate of net
disposal of the class or chemical, and
changes in the rate of net disposal of the
class or chemical by registrants holding
individual manufacturing quotas for the
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
class; (2) whether any increased demand
for that class or chemical, the national
and/or individual rates of net disposal
of that class or chemical are temporary,
short term, or long term; (3) whether any
increased demand for that class or
chemical can be met through existing
inventories, increased individual
manufacturing quotas, or increased
importation, without increasing the
aggregate production quota; (4) whether
any decreased demand for that class or
chemical will result in excessive
inventory accumulation by all persons
registered to handle that class or
chemical; and (5) other factors affecting
medical, scientific, research, and
industrial needs in the United States
and lawful export requirements, as the
Acting Administrator finds relevant.
These quotas do not include imports of
controlled substances for use in
industrial processes.
The Acting Administrator also
considered updated information
obtained from 2016 year-end
inventories, 2016 disposition data
submitted by quota applicants,
estimates of the medical needs of the
United States, product development,
and other information made available to
the DEA after the initial aggregate
production quotas and assessment of
annual needs had been established.
Other factors the Acting Administrator
considered in calculating the aggregate
production quotas, but not the
assessment of annual needs, include
product development requirements of
both bulk and finished dosage form
manufacturers, and other pertinent
information. In determining the
proposed adjusted 2017 assessment of
annual needs, the DEA used the
calculation methodology previously
described in the 2010 and 2011
established assessment of annual needs
(74 FR 60294, Nov. 20, 2009, and 75 FR
79407, Dec. 20, 2010, respectively).
The Acting Administrator, therefore,
proposes that the year 2017 aggregate
production quotas for the nine
temporarily scheduled substances be
established, and to adjust the 2017
aggregate production quotas for certain
schedule I and II controlled substances
and assessment of annual needs for the
list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
E:\FR\FM\04AUN1.SGM
04AUN1
36451
Federal Register / Vol. 82, No. 149 / Friday, August 4, 2017 / Notices
Established 2017
quotas
(g)
Basic class
Proposed
Revised 2017
quotas
(g)
Temporarily Scheduled Substances
4-Fluoroisobutyryl fentanyl ..............................................................................................................................
5F–ADB; 5F–MDMB–PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3dimethylbutanoate).
5F–AMB (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) .............................
5F–APINACA; 5F–AKB48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) ..................
ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3carboxamide).
MDMB–CHMICA; MMB–CHMINACA (methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3dimethylbutanoate).
MDMB–FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) .....
Furanyl fentanyl ..............................................................................................................................................
U–47700 .........................................................................................................................................................
N/A
N/A
30.
30.
N/A
N/A
N/A
30.
30.
30.
N/A
30.
N/A
N/A
N/A
30.
30.
30.
10
30
30
15
25
2
30
30
30
30
30
25
no
no
no
no
no
no
no
no
no
no
no
no
30
25
no change.
no change.
30
5
no change.
30.
25
25
25
30
30
25
55
50
40
40
35
25
2
2
25
25
25
25
150
25
25
45
25
50
40
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
30.
30.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
20
25
25
25
25
15
50
15
100
no change.
no change.
no change.
no change.
no change.
30.
no change.
30.
no change.
Schedule I
1-(1-Phenylcyclohexyl)pyrrolidine ...................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) .......................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ......................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ..............................................................................................................
1-Benzylpiperazine .........................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine ......................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) .....................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) ..................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) ....................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P) ................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) .................................................................................................
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B;
Cimbi-36).
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) ...................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C;
Cimbi-82).
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) ........................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I;
Cimbi-5).
2,5-Dimethoxy-4-ethylamphetamine (DOET) .................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine ................................................................................................
2,5-Dimethoxyamphetamine ...........................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ..........................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) ...................................................................
3,4,5-Trimethoxyamphetamine .......................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) .......................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) ............................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ........................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) .....................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) ......................................................................................................
3–FMC; 3-Fluoro-N-methylcathinone .............................................................................................................
3-Methylfentanyl ..............................................................................................................................................
3-Methylthiofentanyl ........................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) .................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ............................................................................................
4–FMC; Flephedrone ......................................................................................................................................
4–MEC; 4-Methyl-N-ethylcathinone ................................................................................................................
4-Methoxyamphetamine .................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) .................................................................................................
4-Methylaminorex ...........................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ...................................................................................................
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ..........................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ....................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8homolog).
5-Fluoro-PB–22; 5F–PB–22 ...........................................................................................................................
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1Hindol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone .......
5-Methoxy-3,4-methylenedioxyamphetamine .................................................................................................
5-Methoxy-N,N-diisopropyltryptamine .............................................................................................................
5-Methoxy-N,N-dimethyltryptamine ................................................................................................................
AB–CHMINACA ..............................................................................................................................................
AB–FUBINACA ...............................................................................................................................................
AB–PINACA ....................................................................................................................................................
Acetyl Fentanyl ...............................................................................................................................................
VerDate Sep<11>2014
15:13 Aug 03, 2017
Jkt 241001
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
E:\FR\FM\04AUN1.SGM
04AUN1
change.
change.
change.
change.
change.
change.
change.
change.
change.
change.
change.
change.
36452
Federal Register / Vol. 82, No. 149 / Friday, August 4, 2017 / Notices
Established 2017
quotas
(g)
Basic class
Acetyl-alpha-methylfentanyl ............................................................................................................................
Acetyldihydrocodeine ......................................................................................................................................
Acetylmethadol ...............................................................................................................................................
ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ................
AH–7921 .........................................................................................................................................................
Allylprodine .....................................................................................................................................................
Alphacetylmethadol .........................................................................................................................................
alpha-Ethyltryptamine .....................................................................................................................................
Alphameprodine ..............................................................................................................................................
Alphamethadol ................................................................................................................................................
alpha-Methylfentanyl .......................................................................................................................................
alpha-Methylthiofentanyl .................................................................................................................................
alpha-Methyltryptamine (AMT) .......................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) .........................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) .......................................................................................................
Aminorex .........................................................................................................................................................
APINCA, AKB48 (N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) ....................................................
Benzylmorphine ..............................................................................................................................................
Betacetylmethadol ..........................................................................................................................................
beta-Hydroxy-3-methylfentanyl .......................................................................................................................
beta-Hydroxyfentanyl ......................................................................................................................................
beta-Hydroxythiofentanyl ................................................................................................................................
Betameprodine ................................................................................................................................................
Betamethadol ..................................................................................................................................................
Betaprodine .....................................................................................................................................................
Bufotenine .......................................................................................................................................................
Butylone ..........................................................................................................................................................
Butyryl fentanyl ...............................................................................................................................................
Cathinone ........................................................................................................................................................
Codeine methylbromide ..................................................................................................................................
Codeine-N-oxide .............................................................................................................................................
Desomorphine .................................................................................................................................................
Diethyltryptamine ............................................................................................................................................
Difenoxin .........................................................................................................................................................
Dihydromorphine .............................................................................................................................................
Dimethyltryptamine .........................................................................................................................................
Dipipanone ......................................................................................................................................................
Etorphine .........................................................................................................................................................
Fenethylline .....................................................................................................................................................
gamma-Hydroxybutyric acid ...........................................................................................................................
Heroin .............................................................................................................................................................
Hydromorphinol ...............................................................................................................................................
Hydroxypethidine ............................................................................................................................................
Ibogaine ..........................................................................................................................................................
JWH–018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) ................................................................................
JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) .....................................................................................................
JWH–073 (1-Butyl-3-(1-naphthoyl)indole) ......................................................................................................
JWH–081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) .................................................................................
JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .....................................................................................
JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .........................................................................
JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) ......................................................................................
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) ..................................................................................
JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) ......................................................................................
Lysergic acid diethylamide (LSD) ...................................................................................................................
MAB–CHMINACA; ADB–CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1Hindazole-3-carboxamide).
Marihuana .......................................................................................................................................................
Mecloqualone ..................................................................................................................................................
Mescaline ........................................................................................................................................................
Methaqualone .................................................................................................................................................
Methcathinone ................................................................................................................................................
Methyldesorphine ............................................................................................................................................
Methyldihydromorphine ...................................................................................................................................
Morphine methylbromide ................................................................................................................................
Morphine methylsulfonate ...............................................................................................................................
Morphine-N-oxide ...........................................................................................................................................
N,N-Dimethylamphetamine .............................................................................................................................
Naphyrone ......................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ...................................................................................................................
N-Ethylamphetamine ......................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................................
VerDate Sep<11>2014
15:13 Aug 03, 2017
Jkt 241001
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
E:\FR\FM\04AUN1.SGM
Proposed
Revised 2017
quotas
(g)
2
2
2
50
30
2
2
25
2
2
2
2
25
25
25
25
25
2
2
2
2
30
2
4
2
3
25
30
24
5
305
25
25
8,750
1,566,000
35
5
Zero
5
56,200,000
25
2
2
5
35
45
45
30
30
35
30
30
30
10
Zero
472,000
Zero
25
10
25
5
2
5
5
350
25
25
5
24
24
04AUN1
30.
30.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
30.
30.
no change.
no change.
no change.
no change.
no change.
30.
no change.
30.
30.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
30.
330
no change.
no change.
no change.
no change.
no change.
no change.
30.
30.
no change.
45.
no change.
no change.
30.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
40.
30.
no change.
30.
no change.
60.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
36453
Federal Register / Vol. 82, No. 149 / Friday, August 4, 2017 / Notices
Established 2017
quotas
(g)
Basic class
Noracymethadol ..............................................................................................................................................
Norlevorphanol ................................................................................................................................................
Normethadone ................................................................................................................................................
Normorphine ...................................................................................................................................................
Para-fluorofentanyl ..........................................................................................................................................
Parahexyl ........................................................................................................................................................
PB–22; QUPIC ................................................................................................................................................
Pentedrone .....................................................................................................................................................
Pentylone ........................................................................................................................................................
Phenomorphan ...............................................................................................................................................
Pholcodine ......................................................................................................................................................
Psilocybin ........................................................................................................................................................
Psilocyn ...........................................................................................................................................................
SR–18 and RCS–8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) ....................................................
SR–19 and RCS–4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) .......................................................................
Tetrahydrocannabinols ...................................................................................................................................
Thiofentanyl ....................................................................................................................................................
THJ–2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) ................................................
Tilidine .............................................................................................................................................................
Trimeperidine ..................................................................................................................................................
UR–144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ................................................
Proposed
Revised 2017
quotas
(g)
2
52
2
40
5
5
20
25
25
2
5
30
50
45
30
409,000
2
15
25
2
25
no change.
55.
no change.
no change.
25.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
25.
30.
no change.
no change.
no change.
4
4
1,750,000
4,200
2
20,100
12,000,000
42,400,000
10
103,400
40,000,000
45,000,000
15
281,100
2
15,000
820,000
99,000
2
32
1,750,000
2
122,000
58,410,000
5,140,800
4
3
10
8,300
19,000,000
3,706,000
5
9
5
15
23,700,000
25,600,000
1,539,100
no change.
no change.
no change.
no change.
no change.
no change.
no change.
no change.
20.
no change.
no change.
no change.
35.
422,000.
no change.
no change.
1,110,000.
no change.
30.
no change.
no change.
no change.
no change.
no change.
no change.
30.
5.
30.
12,900.
no change.
no change.
no change.
30.
no change.
no change.
no change.
no change.
no change.
Schedule II
1-Phenylcyclohexylamine ...............................................................................................................................
1-Piperidinocyclohexanecarbonitrile ...............................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) ....................................................................................................
Alfentanil .........................................................................................................................................................
Alphaprodine ...................................................................................................................................................
Amobarbital .....................................................................................................................................................
Amphetamine (for conversion) .......................................................................................................................
Amphetamine (for sale) ..................................................................................................................................
Carfentanil .......................................................................................................................................................
Cocaine ...........................................................................................................................................................
Codeine (for conversion) ................................................................................................................................
Codeine (for sale) ...........................................................................................................................................
Dextropropoxyphene .......................................................................................................................................
Dihydrocodeine ...............................................................................................................................................
Dihydroetorphine .............................................................................................................................................
Diphenoxylate (for conversion) .......................................................................................................................
Diphenoxylate (for sale) ..................................................................................................................................
Ecgonine .........................................................................................................................................................
Ethylmorphine .................................................................................................................................................
Etorphine hydrochloride ..................................................................................................................................
Fentanyl ..........................................................................................................................................................
Glutethimide ....................................................................................................................................................
Hydrocodone (for conversion) ........................................................................................................................
Hydrocodone (for sale) ...................................................................................................................................
Hydromorphone ..............................................................................................................................................
Isomethadone .................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ...................................................................................................................
Levomethorphan .............................................................................................................................................
Levorphanol ....................................................................................................................................................
Lisdexamfetamine ...........................................................................................................................................
Meperidine ......................................................................................................................................................
Meperidine Intermediate-A .............................................................................................................................
Meperidine Intermediate-B .............................................................................................................................
Meperidine Intermediate-C .............................................................................................................................
Metazocine ......................................................................................................................................................
Methadone (for sale) ......................................................................................................................................
Methadone Intermediate .................................................................................................................................
Methamphetamine ..........................................................................................................................................
[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 600,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 39,100 grams for methamphetamine (for sale)].
Methylphenidate ..............................................................................................................................................
Morphine (for conversion) ...............................................................................................................................
Morphine (for sale) .........................................................................................................................................
Nabilone ..........................................................................................................................................................
Noroxymorphone (for conversion) ..................................................................................................................
Noroxymorphone (for sale) .............................................................................................................................
VerDate Sep<11>2014
15:13 Aug 03, 2017
Jkt 241001
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
E:\FR\FM\04AUN1.SGM
73,000,000
27,300,000
41,000,000
19,000
17,700,000
400,000
04AUN1
no
no
no
no
no
no
change.
change.
change.
change.
change.
change.
36454
Federal Register / Vol. 82, No. 149 / Friday, August 4, 2017 / Notices
Established 2017
quotas
(g)
Basic class
Opium (powder) ..............................................................................................................................................
Opium (tincture) ..............................................................................................................................................
Oripavine .........................................................................................................................................................
Oxycodone (for conversion) ...........................................................................................................................
Oxycodone (for sale) ......................................................................................................................................
Oxymorphone (for conversion) .......................................................................................................................
Oxymorphone (for sale) ..................................................................................................................................
Pentobarbital ...................................................................................................................................................
Phenazocine ...................................................................................................................................................
Phencyclidine ..................................................................................................................................................
Phenmetrazine ................................................................................................................................................
Phenylacetone ................................................................................................................................................
Racemethorphan ............................................................................................................................................
Racemorphan .................................................................................................................................................
Remifentanil ....................................................................................................................................................
Secobarbital ....................................................................................................................................................
Sufentanil ........................................................................................................................................................
Tapentadol ......................................................................................................................................................
Thebaine .........................................................................................................................................................
90,000
907,200
22,000,000
2,610,000
108,510,000
22,300,000
4,200,000
27,500,000
5
20
2
20
2
2
3,000
172,002
4,000
21,000,000
100,000,000
Proposed
Revised 2017
quotas
(g)
no change.
600,000.
22,700,000.
no change.
no change.
no change.
no change.
no change.
no change.
35.
25.
40.
5.
5.
no change.
no change.
no change.
no change.
no change.
List I Chemicals
Ephedrine (for conversion) .............................................................................................................................
Ephedrine (for sale) ........................................................................................................................................
Phenylpropanolamine (for conversion) ...........................................................................................................
Phenylpropanolamine (for sale) ......................................................................................................................
Pseudoephedrine (for conversion) .................................................................................................................
Pseudoephedrine (for sale) ............................................................................................................................
The Acting Administrator further
proposes that aggregate production
quotas for all other schedule I and II
controlled substances included in 21
CFR 1308.11 and 1308.12 remain at
zero. In accordance with 21 CFR
1303.13 and 21 CFR 1315.13, upon
consideration of the relevant factors, the
Acting Administrator may adjust the
2017 aggregate production quotas and
assessment of annual needs as needed.
Conclusion
After consideration of any comments
or objections, or after a hearing, if one
is held, the Acting Administrator will
issue and publish in the Federal
Register a final order establishing any
adjustment of 2017 aggregate production
quota for each basic class of controlled
substances in schedules I and II and
established assessment of annual needs
for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine, 21 CFR
1303.13(c) and 1315.13(f).
Dated: July 27, 2017.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2017–16440 Filed 8–3–17; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
15:13 Aug 03, 2017
Jkt 241001
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Claim for
Continuance of Compensation
Notice of availability; request
for comments.
ACTION:
The Department of Labor
(DOL) is submitting the Office of
Workers’ Compensation Programs
(OWCP) sponsored information
collection request (ICR) revision titled,
‘‘Claim for Continuance of
Compensation,’’ to the Office of
Management and Budget (OMB) for
review and approval for use in
accordance with the Paperwork
Reduction Act (PRA) of 1995. Public
comments on the ICR are invited.
DATES: The OMB will consider all
written comments that agency receives
on or before September 5, 2017.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov Web site at https://
www.reginfo.gov/public/do/
PRAViewICR?ref_nbr=201703-1240-005
(this link will only become active on the
SUMMARY:
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
50,000
5,360,000
15,000,000
8,500,000
40
200,00,000
no
no
no
no
no
no
change.
change.
change.
change.
change.
change.
day following publication of this notice)
or by contacting Michel Smyth by
telephone at 202–693–4129, TTY 202–
693–8064, (these are not toll-free
numbers) or sending an email to DOL_
PRA_PUBLIC@dol.gov.
Submit comments about this request
by mail or courier to the Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for DOL–
OWCP, Office of Management and
Budget, Room 10235, 725 17th Street
NW., Washington, DC 20503; by Fax:
202–395–5806 (this is not a toll-free
number); or by email: OIRA_
submission@omb.eop.gov. Commenters
are encouraged, but not required, to
send a courtesy copy of any comments
by mail or courier to the U.S.
Department of Labor–OASAM, Office of
the Chief Information Officer, Attn:
Departmental Information Compliance
Management Program, Room N1301,
200 Constitution Avenue NW.,
Washington, DC 20210; or by email:
DOL_PRA_PUBLIC@dol.gov.
FOR FURTHER INFORMATION CONTACT:
Michel Smyth by telephone at 202–693–
4129, TTY 202–693–8064, (these are not
toll-free numbers) or sending an email
to DOL_PRA_PUBLIC@dol.gov.
Authority: 44 U.S.C. 3507(a)(1)(D).
This ICR
seeks approval under the PRA for
revisions to the Claim for Continuance
of Compensation (Form CA–12)
SUPPLEMENTARY INFORMATION:
E:\FR\FM\04AUN1.SGM
04AUN1
]]>Agencies
[Federal Register Volume 82, Number 149 (Friday, August 4, 2017)]
[Notices]
[Pages 36449-36454]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16440]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-470P]
Proposed Adjustments to the Aggregate Production Quotas for
Schedule I and II Controlled Substances and Assessment of Annual Needs
for the List I Chemicals Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2017
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Notice with request for comments.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration (DEA) proposes to adjust
the 2017 aggregate production quotas for several controlled substances
in schedules I and II of the Controlled Substances Act and assessment
of annual needs for the list I chemicals ephedrine, pseudoephedrine,
and phenylpropanolamine.
DATES: Interested persons may file written comments on this notice in
accordance with 21 CFR 1303.13(c) and 1315.13(d). Electronic comments
must be submitted, and written comments must be postmarked, on or
before September 5, 2017. Commenters should be aware that the
electronic Federal Docket Management System will not accept comments
after 11:59 p.m. Eastern Time on the last day of the comment period.
Based on comments received in response to this notice, the
Administrator may hold a public hearing on one or more issues raised.
In the event the Administrator decides in his sole discretion to hold
such a hearing, the Administrator will publish a notice of any such
hearing in the Federal Register. After consideration of any comments or
objections, or after a hearing, if one is held, the Administrator will
publish in the Federal Register a final order establishing the 2017
adjusted aggregate production quotas for schedule I and II controlled
substances, and an assessment of annual needs for the list I chemicals
ephedrine, pseudoephedrine, and phenylpropanolamine.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-470P'' on all correspondence, including any
attachments. The Drug Enforcement Administration encourages that all
comments be submitted electronically through the Federal eRulemaking
Portal which provides the ability to type short comments directly into
the comment field on the Web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the online
instructions at that site for submitting comments. Upon completion of
your submission you will receive a Comment Tracking Number for your
comment. Please be aware that submitted comments are not
instantaneously available for public view on Regulations.gov. If you
have received a Comment Tracking Number, your comment has been
successfully submitted and there is no need to resubmit the same
comment. Paper comments that duplicate electronic submissions are not
necessary and are discouraged. Should you wish to mail a paper comment
in lieu of an electronic comment, it should be sent via regular or
express mail to: Drug Enforcement Administration, Attention: DEA
Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control
Division, Drug Enforcement Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598-
6812.
[[Page 36450]]
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments received in response to this docket
are considered part of the public record. They will, unless reasonable
cause is given, be made available by the Drug Enforcement
Administration (DEA) for public inspection online at https://www.regulations.gov. Such information includes personal identifying
information (such as your name, address, etc.) voluntarily submitted by
the commenter.
The Freedom of Information Act (FOIA) applies to all comments
received. If you want to submit personal identifying information (such
as your name, address, etc.) as part of your comment, but do not want
it to be made publicly available, you must include the phrase
``PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your
comment. You must also place all the personal identifying information
you do not want made publicly available in the first paragraph of your
comment and identify what information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be made publicly available, you
must include the phrase ``CONFIDENTIAL BUSINESS INFORMATION'' in the
first paragraph of your comment. You must also prominently identify
confidential business information to be redacted within the comment.
Comments containing personal identifying information or
confidential business information identified and located as directed
above will generally be made available in redacted form. If a comment
contains so much confidential business information or personal
identifying information that it cannot be effectively redacted, all or
part of that comment may not be made publicly available. Comments
posted to https://www.regulations.gov may include any personal
identifying information (such as name, address, and phone number)
included in the text of your electronic submission that is not
identified as directed above as confidential.
An electronic copy of this document is available at https://www.regulations.gov for easy reference.
Legal Authority and Background
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
for each basic class of controlled substance listed in schedules I and
II and for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. The Attorney General has delegated this function
to the Administrator of the DEA pursuant to 28 CFR 0.100.
The DEA established the 2017 aggregate production quotas for
substances in schedules I and II and the assessment of annual needs for
the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine on October 5, 2016 (81 FR 69079). That notice
stipulated that, in accordance with 21 CFR 1303.13 and 1315.13, all
aggregate production quotas and assessments of annual need are subject
to adjustment.
Analysis for Proposed Adjusted 2017 Aggregate Production Quotas and
Assessment of Annual Needs
The DEA proposes to adjust the established 2017 aggregate
production quotas and assessment of annual needs for certain schedule I
and II controlled substances, and the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine, to be manufactured in the
United States in 2017 to provide for the estimated medical, scientific,
research, and industrial needs of the United States, for lawful export
requirements, and for the establishment and maintenance of reserve
stocks. These quotas do not include imports of controlled substances
for use in industrial processes.
In determining the proposed adjustment, the Acting Administrator
has taken into account the criteria in accordance with 21 CFR 1303.13
(adjustment of aggregate production quotas for controlled substances)
and 21 CFR 1315.13 (adjustment of the assessment of annual needs for
ephedrine, pseudoephedrine, and phenylpropanolamine). The DEA
determined whether to propose an adjustment of the aggregate production
quotas and assessment of annual needs for 2017 by considering: (1)
Changes in the demand for that class or chemical, changes in the
national rate of net disposal of the class or chemical, and changes in
the rate of net disposal of the class or chemical by registrants
holding individual manufacturing quotas for the class; (2) whether any
increased demand for that class or chemical, the national and/or
individual rates of net disposal of that class or chemical are
temporary, short term, or long term; (3) whether any increased demand
for that class or chemical can be met through existing inventories,
increased individual manufacturing quotas, or increased importation,
without increasing the aggregate production quota; (4) whether any
decreased demand for that class or chemical will result in excessive
inventory accumulation by all persons registered to handle that class
or chemical; and (5) other factors affecting medical, scientific,
research, and industrial needs in the United States and lawful export
requirements, as the Acting Administrator finds relevant. These quotas
do not include imports of controlled substances for use in industrial
processes.
The Acting Administrator also considered updated information
obtained from 2016 year-end inventories, 2016 disposition data
submitted by quota applicants, estimates of the medical needs of the
United States, product development, and other information made
available to the DEA after the initial aggregate production quotas and
assessment of annual needs had been established. Other factors the
Acting Administrator considered in calculating the aggregate production
quotas, but not the assessment of annual needs, include product
development requirements of both bulk and finished dosage form
manufacturers, and other pertinent information. In determining the
proposed adjusted 2017 assessment of annual needs, the DEA used the
calculation methodology previously described in the 2010 and 2011
established assessment of annual needs (74 FR 60294, Nov. 20, 2009, and
75 FR 79407, Dec. 20, 2010, respectively).
The Acting Administrator, therefore, proposes that the year 2017
aggregate production quotas for the nine temporarily scheduled
substances be established, and to adjust the 2017 aggregate production
quotas for certain schedule I and II controlled substances and
assessment of annual needs for the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine, expressed in grams of
anhydrous acid or base, as follows:
[[Page 36451]]
------------------------------------------------------------------------
Established 2017 Proposed Revised
Basic class quotas (g) 2017 quotas (g)
------------------------------------------------------------------------
Temporarily Scheduled Substances
------------------------------------------------------------------------
4-Fluoroisobutyryl fentanyl... N/A 30.
5F-ADB; 5F-MDMB-PINACA (methyl N/A 30.
2-(1-(5-fluoropentyl)-1H-
indazole-3-carboxamido)-3,3-
dimethylbutanoate).
5F-AMB (methyl 2-(1-(5- N/A 30.
fluoropentyl)-1H-indazole-3-
carboxamido)-3-
methylbutanoate).
5F-APINACA; 5F-AKB48 (N- N/A 30.
(adamantan-1-yl)-1-(5-
fluoropentyl)-1H-indazole-3-
carboxamide).
ADB-FUBINACA (N-(1-amino-3,3- N/A 30.
dimethyl-1-oxobutan-2-yl)-1-
(4-fluorobenzyl)-1H-indazole-
3-carboxamide).
MDMB-CHMICA; MMB-CHMINACA N/A 30.
(methyl 2-(1-
(cyclohexylmethyl)-1H-indole-
3-carboxamido)-3,3-
dimethylbutanoate).
MDMB-FUBINACA (methyl 2-(1-(4- N/A 30.
fluorobenzyl)-1H-indazole-3-
carboxamido)-3,3-
dimethylbutanoate).
Furanyl fentanyl.............. N/A 30.
U-47700....................... N/A 30.
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
1-(1- 10 no change.
Phenylcyclohexyl)pyrrolidine.
1-(5-Fluoropentyl)-3-(1- 30 no change.
naphthoyl)indole (AM2201).
1-(5-Fluoropentyl)-3-(2- 30 no change.
iodobenzoyl)indole (AM694).
1-[1-(2- 15 no change.
Thienyl)cyclohexyl]piperidine.
1-Benzylpiperazine............ 25 no change.
1-Methyl-4-phenyl-4- 2 no change.
propionoxypiperidine.
2-(2,5-Dimethoxy-4- 30 no change.
ethylphenyl)ethanamine (2C-E).
2-(2,5-Dimethoxy-4- 30 no change.
methylphenyl)ethanamine (2C-
D).
2-(2,5-Dimethoxy-4-nitro- 30 no change.
phenyl)ethanamine (2C-N).
2-(2,5-Dimethoxy-4-n- 30 no change.
propylphenyl)ethanamine (2C-
P).
2-(2,5- 30 no change.
Dimethoxyphenyl)ethanamine
(2C-H).
2-(4-Bromo-2,5- 25 no change.
dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25B-
NBOMe; 2C-B-NBOMe; 25B; Cimbi-
36).
2-(4-Chloro-2,5- 30 no change.
dimethoxyphenyl)ethanamine
(2C-C).
2-(4-Chloro-2,5- 25 no change.
dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25C-
NBOMe; 2C-C-NBOMe; 25C; Cimbi-
82).
2-(4-Iodo-2,5- 30 no change.
dimethoxyphenyl)ethanamine
(2C-I).
2-(4-Iodo-2,5-dimethoxyphenyl)- 5 30.
N-(2-methoxybenzyl)ethanamine
(25I-NBOMe; 2C-I-NBOMe; 25I;
Cimbi-5).
2,5-Dimethoxy-4- 25 no change.
ethylamphetamine (DOET).
2,5-Dimethoxy-4-n- 25 no change.
propylthiophenethylamine.
2,5-Dimethoxyamphetamine...... 25 no change.
2-[4-(Ethylthio)-2,5- 30 no change.
dimethoxyphenyl]ethanamine
(2C-T-2).
2-[4-(Isopropylthio)-2,5- 30 no change.
dimethoxyphenyl]ethanamine
(2C-T-4).
3,4,5-Trimethoxyamphetamine... 25 no change.
3,4-Methylenedioxyamphetamine 55 no change.
(MDA).
3,4- 50 no change.
Methylenedioxymethamphetamine
(MDMA).
3,4-Methylenedioxy-N- 40 no change.
ethylamphetamine (MDEA).
3,4-Methylenedioxy-N- 40 no change.
methylcathinone (methylone).
3,4-Methylenedioxypyrovalerone 35 no change.
(MDPV).
3-FMC; 3-Fluoro-N- 25 no change.
methylcathinone.
3-Methylfentanyl.............. 2 30.
3-Methylthiofentanyl.......... 2 30.
4-Bromo-2,5- 25 no change.
dimethoxyamphetamine (DOB).
4-Bromo-2,5- 25 no change.
dimethoxyphenethylamine (2-
CB).
4-FMC; Flephedrone............ 25 no change.
4-MEC; 4-Methyl-N- 25 no change.
ethylcathinone.
4-Methoxyamphetamine.......... 150 no change.
4-Methyl-2,5- 25 no change.
dimethoxyamphetamine (DOM).
4-Methylaminorex.............. 25 no change.
4-Methyl-N-methylcathinone 45 no change.
(mephedrone).
4-Methyl-[alpha]- 25 no change.
pyrrolidinopropiophenone (4-
MePPP).
5-(1,1-Dimethylheptyl)-2- 50 no change.
[(1R,3S)-3-hydroxycyclohexyl]-
phenol.
5-(1,1-Dimethyloctyl)-2- 40 no change.
[(1R,3S)-3-hydroxycyclohexyl]-
phenol (cannabicyclohexanol
or CP-47,497 C8-homolog).
5-Fluoro-PB-22; 5F-PB-22...... 20 no change.
5-Fluoro-UR144, XLR11 ([1-(5- 25 no change.
fluoro-pentyl)-1Hindol-3-
yl](2,2,3,3-
tetramethylcyclopropyl)methan
one.
5-Methoxy-3,4- 25 no change.
methylenedioxyamphetamine.
5-Methoxy-N,N- 25 no change.
diisopropyltryptamine.
5-Methoxy-N,N- 25 no change.
dimethyltryptamine.
AB-CHMINACA................... 15 30.
AB-FUBINACA................... 50 no change.
AB-PINACA..................... 15 30.
Acetyl Fentanyl............... 100 no change.
[[Page 36452]]
Acetyl-alpha-methylfentanyl... 2 30.
Acetyldihydrocodeine.......... 2 30.
Acetylmethadol................ 2 no change.
ADB-PINACA (N-(1-amino-3,3- 50 no change.
dimethyl-1-oxobutan-2-yl)-1-
pentyl-1H-indazole-3-
carboxamide).
AH-7921....................... 30 no change.
Allylprodine.................. 2 no change.
Alphacetylmethadol............ 2 no change.
alpha-Ethyltryptamine......... 25 no change.
Alphameprodine................ 2 no change.
Alphamethadol................. 2 no change.
alpha-Methylfentanyl.......... 2 30.
alpha-Methylthiofentanyl...... 2 30.
alpha-Methyltryptamine (AMT).. 25 no change.
alpha-Pyrrolidinobutiophenone 25 no change.
([alpha]-PBP).
alpha-Pyrrolidinopentiophenone 25 no change.
([alpha]-PVP).
Aminorex...................... 25 no change.
APINCA, AKB48 (N-(1-adamantyl)- 25 no change.
1-pentyl-1H-indazole-3-
carboxamide).
Benzylmorphine................ 2 30.
Betacetylmethadol............. 2 no change.
beta-Hydroxy-3-methylfentanyl. 2 30.
beta-Hydroxyfentanyl.......... 2 30.
beta-Hydroxythiofentanyl...... 30 no change.
Betameprodine................. 2 no change.
Betamethadol.................. 4 no change.
Betaprodine................... 2 no change.
Bufotenine.................... 3 no change.
Butylone...................... 25 no change.
Butyryl fentanyl.............. 30 no change.
Cathinone..................... 24 no change.
Codeine methylbromide......... 5 30.
Codeine-N-oxide............... 305 330
Desomorphine.................. 25 no change.
Diethyltryptamine............. 25 no change.
Difenoxin..................... 8,750 no change.
Dihydromorphine............... 1,566,000 no change.
Dimethyltryptamine............ 35 no change.
Dipipanone.................... 5 no change.
Etorphine..................... Zero 30.
Fenethylline.................. 5 30.
gamma-Hydroxybutyric acid..... 56,200,000 no change.
Heroin........................ 25 45.
Hydromorphinol................ 2 no change.
Hydroxypethidine.............. 2 no change.
Ibogaine...................... 5 30.
JWH-018 and AM678 (1-Pentyl-3- 35 no change.
(1-naphthoyl)indole).
JWH-019 (1-Hexyl-3-(1- 45 no change.
naphthoyl)indole).
JWH-073 (1-Butyl-3-(1- 45 no change.
naphthoyl)indole).
JWH-081 (1-Pentyl-3-[1-(4- 30 no change.
methoxynaphthoyl)]indole).
JWH-122 (1-Pentyl-3-(4-methyl- 30 no change.
1-naphthoyl)indole).
JWH-200 (1-[2-(4- 35 no change.
Morpholinyl)ethyl]-3-(1-
naphthoyl)indole).
JWH-203 (1-Pentyl-3-(2- 30 no change.
chlorophenylacetyl)indole).
JWH-250 (1-Pentyl-3-(2- 30 no change.
methoxyphenylacetyl)indole).
JWH-398 (1-Pentyl-3-(4-chloro- 30 no change.
1-naphthoyl)indole).
Lysergic acid diethylamide 10 40.
(LSD).
MAB-CHMINACA; ADB-CHMINACA (N- Zero 30.
(1-amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-
indazole-3-carboxamide).
Marihuana..................... 472,000 no change.
Mecloqualone.................. Zero 30.
Mescaline..................... 25 no change.
Methaqualone.................. 10 60.
Methcathinone................. 25 no change.
Methyldesorphine.............. 5 no change.
Methyldihydromorphine......... 2 no change.
Morphine methylbromide........ 5 no change.
Morphine methylsulfonate...... 5 no change.
Morphine-N-oxide.............. 350 no change.
N,N-Dimethylamphetamine....... 25 no change.
Naphyrone..................... 25 no change.
N-Ethyl-1- 5 no change.
phenylcyclohexylamine.
N-Ethylamphetamine............ 24 no change.
N-Hydroxy-3,4- 24 no change.
methylenedioxyamphetamine.
[[Page 36453]]
Noracymethadol................ 2 no change.
Norlevorphanol................ 52 55.
Normethadone.................. 2 no change.
Normorphine................... 40 no change.
Para-fluorofentanyl........... 5 25.
Parahexyl..................... 5 no change.
PB-22; QUPIC.................. 20 no change.
Pentedrone.................... 25 no change.
Pentylone..................... 25 no change.
Phenomorphan.................. 2 no change.
Pholcodine.................... 5 no change.
Psilocybin.................... 30 no change.
Psilocyn...................... 50 no change.
SR-18 and RCS-8 (1- 45 no change.
Cyclohexylethyl-3-(2-
methoxyphenylacetyl)indole).
SR-19 and RCS-4 (1-Pentyl-3- 30 no change.
[(4-methoxy)-benzoyl]indole).
Tetrahydrocannabinols......... 409,000 no change.
Thiofentanyl.................. 2 25.
THJ-2201 ([1-(5-fluoropentyl)- 15 30.
1H-indazol-3-yl](naphthalen-1-
yl)methanone).
Tilidine...................... 25 no change.
Trimeperidine................. 2 no change.
UR-144 (1-pentyl-1H-indol-3- 25 no change.
yl)(2,2,3,3-
tetramethylcyclopropyl)methan
one.
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine....... 4 no change.
1- 4 no change.
Piperidinocyclohexanecarbonit
rile.
4-Anilino-N-phenethyl-4- 1,750,000 no change.
piperidine (ANPP).
Alfentanil.................... 4,200 no change.
Alphaprodine.................. 2 no change.
Amobarbital................... 20,100 no change.
Amphetamine (for conversion).. 12,000,000 no change.
Amphetamine (for sale)........ 42,400,000 no change.
Carfentanil................... 10 20.
Cocaine....................... 103,400 no change.
Codeine (for conversion)...... 40,000,000 no change.
Codeine (for sale)............ 45,000,000 no change.
Dextropropoxyphene............ 15 35.
Dihydrocodeine................ 281,100 422,000.
Dihydroetorphine.............. 2 no change.
Diphenoxylate (for conversion) 15,000 no change.
Diphenoxylate (for sale)...... 820,000 1,110,000.
Ecgonine...................... 99,000 no change.
Ethylmorphine................. 2 30.
Etorphine hydrochloride....... 32 no change.
Fentanyl...................... 1,750,000 no change.
Glutethimide.................. 2 no change.
Hydrocodone (for conversion).. 122,000 no change.
Hydrocodone (for sale)........ 58,410,000 no change.
Hydromorphone................. 5,140,800 no change.
Isomethadone.................. 4 30.
Levo-alphacetylmethadol (LAAM) 3 5.
Levomethorphan................ 10 30.
Levorphanol................... 8,300 12,900.
Lisdexamfetamine.............. 19,000,000 no change.
Meperidine.................... 3,706,000 no change.
Meperidine Intermediate-A..... 5 no change.
Meperidine Intermediate-B..... 9 30.
Meperidine Intermediate-C..... 5 no change.
Metazocine.................... 15 no change.
Methadone (for sale).......... 23,700,000 no change.
Methadone Intermediate........ 25,600,000 no change.
Methamphetamine............... 1,539,100 no change.
------------------------------------------------------------------------
[900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-
prescription product; 600,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 39,100 grams for
methamphetamine (for sale)].
------------------------------------------------------------------------
Methylphenidate............... 73,000,000 no change.
Morphine (for conversion)..... 27,300,000 no change.
Morphine (for sale)........... 41,000,000 no change.
Nabilone...................... 19,000 no change.
Noroxymorphone (for 17,700,000 no change.
conversion).
Noroxymorphone (for sale)..... 400,000 no change.
[[Page 36454]]
Opium (powder)................ 90,000 no change.
Opium (tincture).............. 907,200 600,000.
Oripavine..................... 22,000,000 22,700,000.
Oxycodone (for conversion).... 2,610,000 no change.
Oxycodone (for sale).......... 108,510,000 no change.
Oxymorphone (for conversion).. 22,300,000 no change.
Oxymorphone (for sale)........ 4,200,000 no change.
Pentobarbital................. 27,500,000 no change.
Phenazocine................... 5 no change.
Phencyclidine................. 20 35.
Phenmetrazine................. 2 25.
Phenylacetone................. 20 40.
Racemethorphan................ 2 5.
Racemorphan................... 2 5.
Remifentanil.................. 3,000 no change.
Secobarbital.................. 172,002 no change.
Sufentanil.................... 4,000 no change.
Tapentadol.................... 21,000,000 no change.
Thebaine...................... 100,000,000 no change.
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion).... 50,000 no change.
Ephedrine (for sale).......... 5,360,000 no change.
Phenylpropanolamine (for 15,000,000 no change.
conversion).
Phenylpropanolamine (for sale) 8,500,000 no change.
Pseudoephedrine (for 40 no change.
conversion).
Pseudoephedrine (for sale).... 200,00,000 no change.
------------------------------------------------------------------------
The Acting Administrator further proposes that aggregate production
quotas for all other schedule I and II controlled substances included
in 21 CFR 1308.11 and 1308.12 remain at zero. In accordance with 21 CFR
1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors,
the Acting Administrator may adjust the 2017 aggregate production
quotas and assessment of annual needs as needed.
Conclusion
After consideration of any comments or objections, or after a
hearing, if one is held, the Acting Administrator will issue and
publish in the Federal Register a final order establishing any
adjustment of 2017 aggregate production quota for each basic class of
controlled substances in schedules I and II and established assessment
of annual needs for the list I chemicals ephedrine, pseudoephedrine,
and phenylpropanolamine, 21 CFR 1303.13(c) and 1315.13(f).
Dated: July 27, 2017.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2017-16440 Filed 8-3-17; 8:45 am]
BILLING CODE 4410-09-P
